FDA Approves NGS-Based CDx for Non-Small Cell Lung Cancer

On December 9, 2021, the U.S. Food and Drug Administration (FDA) granted premarket approval to Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify patients with non-small cell lung cancer whose tumors carry epidermal growth factor receptor Exon20-insertion mutations for potential treatment with Rybrevant® (amivantamab-vmjw).

Read ThermoFisher Scientific's announcement.

Posted 12/10/2021